BioCentury
ARTICLE | Financial News

Stemline sets IPO range

July 20, 2012 12:23 AM UTC

Stemline Therapeutics Inc. (New York, N.Y.) amended its IPO and now plans to sell 3.5 million shares at $11-$13. A $12 price would raise $42 million and value the company at $127.9 million. RBC Capital Markets; Oppenheimer; and JMP Securities are underwriters. In April, Stemline filed to raise up to $50 million. ...